No Data
No Data
Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Mizuho analyst Graig Suvannavejh maintains Corvus Pharma with a Neutral and maintains $3.5 price target.
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus Pharmaceuticals: Insider Ownership Raises Power Concentration Concerns
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7
Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7.
Corvus Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 246.53% Oppenheimer $8 → $7 Maintains Outperform 09/07/2023 98.02% Cantor Fitzgerald → $4 Reite
No Data